TargaGenix, Inc.

TargaGenix is developing novel cancer therapies that target cancer stem cells.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Stony Brook, NY, USA
  • Currency USD
  • Founded June 2013
  • Employees 3

Company Summary

TargaGenix, Inc. is developing a novel therapy for the treatment of cancer that targets cancer stem cells and bulk tumor cells. The product, DHA-SBT-1214 was the result of a 10+ year effort to discover new molecules that were effective against chemotherapy resistant tumors and has been shown in preclinical models that it can treat and cure animals with tumor types that are resistant to current chemotherapy treatments.

Team

  • James Egan
    President and CEO

    Dr. Egan has extensive experience in both academic and commercial drug development. Most recently Dr. Egan has served as Director of Business development at IRX Therapeutics, a clinical stage biopharmaceutical company. In this role he was responsible for raising over $90mm to fund the development of their lead product. Dr. Egan negotiated the option to sell the company in 2014.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free